Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-01-30
1996-04-30
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514422, 514443, A61K 31445, A61K 3140, A61K 3138
Patent
active
055125832
ABSTRACT:
A method of lowering serum calcium levels comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.l and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5075321 (1991-12-01), Schreiber
patent: 5393763 (1995-02-01), Black et al.
U.S. application Ser. No. 07/920,933 filed Jul. 28, 1992 to Black et al.
U.S. application Ser. No. 07/995,222 filed Dec. 22, 1992 to Black et al.
U.S. application Ser. No. 08/035,121 filed Mar. 19, 1993 to Black et al.
U.S. application Ser. No. 08/082218 filed Jun. 24, 1993 to Cullinan et al.
U.S. application Ser. No. 08/096,480 filed Jul. 22, 1993 to Hock.
U.S. application Ser. No. 08/112,012 filed Aug. 15, 1993 to Dodge et al.
U.S. application Ser. No. 08/111,796 filed Aug. 25, 1993 to Dodge et al.
U.S. application Ser. No. 08/081,610 filed Jun. 21, 1993 to Yang.
Draper et al., "Effects of Raloxifene (LY139481 HCl) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth Int'l. Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Evans et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;" .Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109;1981, 987-989.
Black, L. J. "Biological Actions and Binding Properties of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M. K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetcs and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of 3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl! 4- 2-pyrrolidinyl)ethoxyl!-phenyl! methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966.
Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo b!thiophene Derivatives Leading to 6-Hydroxy-2-(4-hydroxyphenyl)benzo b!thien-3-yl! 4- 2-(1-piperidinyl)etho xy!-phenyl!methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.
Prince et al., J. Clin. Endorin. and Metab., 72(6) 1226-1228 (1991).
Prince et al., J. Clin. Endorin. and Metab., 71(5) 1284-1287, (1990).
Boss Susan M.
Dere Willard H.
Eli Lilly and Company
Jordan Kimberly
Sales James J.
LandOfFree
Methods of decreasing serum calcium levels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of decreasing serum calcium levels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of decreasing serum calcium levels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-629032